The global Prostate Cancer Biomarker Market was valued at USD 4.60 billion in 2024 and is projected to reach USD 15.58 billion by 2034, registering a robust CAGR of 13.00% from 2025 to 2034. This impressive expansion is primarily fueled by the rising prevalence of prostate cancer among aging populations globally. According to a December 2024 CDC report, the US recorded 236,659 prostate cancer cases in 2021, with an incidence rate of 112 per 100,000 males. Approximately 70% of these cases were diagnosed at the localized stage, highlighting the critical need for effective early detection tools.
The increasing proportion of elderly individuals globally has led to a greater incidence of prostate cancer diagnoses, as age is a primary risk factor. This demographic shift necessitates improved screening, monitoring, and diagnostic approaches. As the demand for early and accurate diagnosis surges, the prostate cancer diagnostics market is experiencing significant momentum. Healthcare systems are increasingly adopting reliable prostate cancer screening biomarkers to manage the growing patient burden effectively. A key driver in this space is PSA testing market growth. Protein biomarkers, particularly prostate-specific antigen (PSA), dominated the market in 2024 due to their widespread clinical use, cost-effectiveness, and robust validation across various stages of disease management.
Read More @ https://www.polarismarketresearch.com/industry-analysis/prostate-cancer-biomarker-market
Furthermore, the broader cancer biomarker testing market is benefiting from continuous advancements in biomarker technologies. Innovations such as AI and network biology frameworks—like Scipher Medicine’s PRoBeNet launched in July 2024—are accelerating biomarker discovery. These technological leaps are enhancing the accuracy of detection, staging, and therapeutic monitoring. North America held the largest revenue share in 2024, driven by advanced healthcare infrastructure and high awareness levels, while the Asia Pacific region is projected to witness the fastest growth during the forecast period. Ultimately, the integration of advanced prostate cancer biomarker solutions is transforming patient outcomes by enabling timely interventions and personalized treatment strategies.
More Trending Latest Reports By Polaris Market Research:
STI And Vaginitis PCR Testing Market
Clinical Oncology Next Generation Sequencing Market
